专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009099631A1 NOVEL PLASMINOGEN RECEPTOR, POLYPEPTIDES & ANTIBODIES THEREOF 审中-公开
标题翻译：新型PLASMINOGEN受体，其多肽和抗体
公开(公告)号：WO2009099631A1
公开(公告)日：2009-08-13
申请号：PCT/US2009/000744
申请日：2009-02-06
申请人： MILES, Lindsey A. , YATES, John , CHEN, Emily I. , BAIK, Nagyung , PARMER, Robert J.
发明人： MILES, Lindsey A. , YATES, John , CHEN, Emily I. , BAIK, Nagyung , PARMER, Robert J.
IPC分类号： C07K14/435
CPC分类号： C07K14/745
摘要： The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-R KT , or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin 1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator and Lipoprotein(a). Plasminogen receptors function to modulate cell surface proteolysis and physiological and pathophysiological processes requiring cell migration, including, but not limited to, cell migration during inflammation, tissue remodeling, wound healing, tumor cell invasion and metastasis, skeletal myogenesis, neurite outgrowth. Plasminogen receptors also modulate apoptosis and cell death. The invention also relates to antibodies that inhibit plasminogen, plasminogen fragments such as angiostatin 1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator or Lipoprotein(a) binding to Plg-R KT and/or immunoreact with Plg-R KT .
摘要翻译：本发明涉及C9orf46同源物，一种新型鼠膜蛋白及其在人，小鼠和所有其他物种中的直向同源物，称为Plg-RKT或其类似物，以及分离方法。该分子的功能是结合纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活物和脂蛋白（a）。纤溶酶原受体起调节细胞表面蛋白水解和需要细胞迁移的生理和病理生理过程，包括但不限于炎症，组织重塑，伤口愈合，肿瘤细胞侵袭和转移中的细胞迁移，骨骼肌发生，神经突生长。纤溶酶原受体也调节凋亡和细胞死亡。本发明还涉及抑制纤溶酶原，纤溶酶原片段如血管抑素1和具有血管抑制活性的其它纤溶酶原片段，组织纤溶酶原激活物或脂蛋白（a）结合Plg-RKT和/或与Plg-RKT的免疫反应的抗体。

IPRDB

热门服务

关于我们

友情链接

联系方式